Carisma Therapeutics (CARM) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free CARM Stock Alerts $1.48 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 12:41 PM | msn.comCarisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis TreatmentMay 13 at 5:58 AM | americanbankingnews.comHC Wainwright Cuts Carisma Therapeutics (NASDAQ:CARM) Price Target to $8.00May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment DevelopmentsMay 10, 2024 | marketbeat.comHC Wainwright Trims Carisma Therapeutics (NASDAQ:CARM) Target Price to $8.00HC Wainwright dropped their price objective on shares of Carisma Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday.May 10, 2024 | markets.businessinsider.comBuy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market GrowthMay 9, 2024 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | prnewswire.comCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | prnewswire.comCarisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024May 7, 2024 | msn.comCarisma Therapeutics Appoints Renowned Oncologist as Chief Medical OfficerMay 6, 2024 | prnewswire.comCarisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 2, 2024 | prnewswire.comCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerApril 24, 2024 | finance.yahoo.comCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingApril 22, 2024 | prnewswire.comCarisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ OutlookApril 12, 2024 | markets.businessinsider.comPromising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating AnalysisApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline PotentialApril 11, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of "Buy" from AnalystsShares of Carisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) have been assigned an average rating of "Buy" from the five research firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month target priceApril 11, 2024 | marketbeat.comCarisma Therapeutics (NASDAQ:CARM) Research Coverage Started at BTIG ResearchBTIG Research initiated coverage on shares of Carisma Therapeutics in a research report on Thursday. They set a "buy" rating and a $6.00 price objective on the stock.April 8, 2024 | msn.comCarisma Therapeutics Welcomes New Board Member John Hohneker Amid Company EvolutionApril 4, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Carisma Therapeutics, Inc. Issued By Capital One Financial (NASDAQ:CARM)Carisma Therapeutics, Inc. (NASDAQ:CARM - Free Report) - Analysts at Capital One Financial lifted their Q1 2024 earnings estimates for shares of Carisma Therapeutics in a research report issued on Tuesday, April 2nd. Capital One Financial analyst N. Quibria now expects that the company will postApril 4, 2024 | seekingalpha.comWall Street Breakfast Podcast: Perma-Fix Advances In PFAS Chemical EliminationApril 3, 2024 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming ConferencesApril 3, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Expected to Post FY2028 Earnings of ($1.93) Per ShareCarisma Therapeutics, Inc. (NASDAQ:CARM - Free Report) - Equities researchers at Capital One Financial issued their FY2028 earnings per share (EPS) estimates for shares of Carisma Therapeutics in a report released on Tuesday, April 2nd. Capital One Financial analyst N. Quibria anticipates that thApril 2, 2024 | marketbeat.comCarisma Therapeutics (NASDAQ:CARM) Price Target Cut to $9.00HC Wainwright cut their price target on shares of Carisma Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Tuesday.April 1, 2024 | bizjournals.comPenn spinout Carisma Therapeutics reducing workforce by 37%April 1, 2024 | finance.yahoo.comCarisma Therapeutics Announces Changes to its Board of DirectorsApril 1, 2024 | finance.yahoo.comCarisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 25.5% in MarchCarisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 1,550,000 shares, a decrease of 25.5% from the February 29th total of 2,080,000 shares. Approximately 8.2% of the company's stock are short sold. Based on an average daily trading volume, of 146,300 shares, the days-to-cover ratio is presently 10.6 days.March 26, 2024 | msn.comCarisma Therapeutics to Highlight Breakthroughs in Cancer Immunotherapy at AACR Annual MeetingMarch 21, 2024 | finance.yahoo.comCarisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingMarch 16, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Sees Significant Decrease in Short InterestCarisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest totalling 2,080,000 shares, a drop of 13.3% from the February 14th total of 2,400,000 shares. Currently, 11.1% of the shares of the stock are sold short. Based on an average daily volume of 166,900 shares, the days-to-cover ratio is presently 12.5 days.March 6, 2024 | msn.comCarisma Therapeutics' CEO to Share Insights at TD Cowen Health Care ConferenceFebruary 28, 2024 | finance.yahoo.comCarisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care ConferenceFebruary 28, 2024 | prnewswire.comCarisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comIndividual investors account for 30% of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) ownership, while institutions account for 23%February 5, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of "Buy" by BrokeragesShares of Carisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1-year targetJanuary 7, 2024 | seekingalpha.comCarisma Therapeutics: New Frontiers In Cell Therapy, But Too Early To Buy InJanuary 2, 2024 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 8.2% in DecemberCarisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,250,000 shares, a decline of 8.2% from the November 30th total of 2,450,000 shares. Based on an average daily volume of 218,300 shares, the days-to-cover ratio is currently 10.3 days. Approximately 12.1% of the company's stock are short sold.December 21, 2023 | finance.yahoo.comCarisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2023 | marketbeat.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of "Buy" from BrokeragesShares of Carisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) have been assigned an average rating of "Buy" from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year pricDecember 15, 2023 | markets.businessinsider.comInnovative CAR-M Therapy Advancements Fuel Buy Rating for Carisma TherapeuticsDecember 9, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn SituationDecember 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lantheus (LNTH) and Carisma Therapeutics (CARM)November 28, 2023 | markets.businessinsider.comCarisma Therapeutics Announces FDA Clearance Of IND For CT-0525 - Quick FactsNovember 28, 2023 | markets.businessinsider.comCarisma Therapeutics Gets FDA Clearance To Start Phase 1 Study Of CT-0525 In Solid TumorsNovember 28, 2023 | finance.yahoo.comCarisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-MonocyteNovember 22, 2023 | finance.yahoo.comCarisma Therapeutics to Participate in Evercore ISI HealthCONx ConferenceNovember 11, 2023 | finance.yahoo.comBenign Growth For Carisma Therapeutics, Inc. (NASDAQ:CARM) Underpins Stock's 42% PlummetNovember 9, 2023 | finance.yahoo.comCarisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsOctober 25, 2023 | finance.yahoo.comCarisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023 Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. CARM Media Mentions By Week CARM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CARM News Sentiment▼-0.120.57▲Average Medical News Sentiment CARM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CARM Articles This Week▼141▲CARM Articles Average Week Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mural Oncology News MediciNova News Kronos Bio News Equillium News Viveon Health Acquisition News Aileron Therapeutics News Eagle Pharmaceuticals News Kezar Life Sciences News Checkpoint Therapeutics News Journey Medical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CARM) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry ResearchThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
